YK-4-279 inhibits ETS fusion-positive prostate cancer (in mice)


An new article in PLOS ONE describes the development of a possible new drug that can prevent tumor growth and spread in mice with prostate cancer and a common but specific chromosomal abnormality.

We are always very cautious about this sort of pre-human research because mice are not men, and there are lot of steps that need to be taken before a drug is actually proven to be effective and safe in clinical practice. The research reported by Rahim et al. is, however, interesting because it is the first time that anyone has been able to show activity of a drug specifically designed to inhibit the effects of the ETV1 protein, which is commonly over-expressed in ETS fusion-positive prostate cancer, and thus inhibit primary tumor growth and metastasis of ETS fusion-positive prostate cancer.

As the authors state in their article,

Our results demonstrate that YK-4-279 is a potent inhibitor of ETV1 and inhibits both the primary tumor growth and metastasis of fusion positive prostate cancer xenografts. Therefore, YK-4-279 or similar compounds may be evaluated as a potential therapeutic tool for treatment of human prostate cancer at different stages.

Clearly this research is promising, and we will need to keep an eye on whether YK-4-279 or other, comparable ETV1 inhibitors can actually be brought to clinical trials in man. (See also this report on the ScienceDaily web site.)

One Response

  1. Did we ever tell you that you are providing an extremely valuable service with this site?

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: